INmune Bio
INMB
26 hedge funds and large institutions have $15M invested in INmune Bio in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
46% more capital invested
Capital invested by funds: $10.3M → $15M (+$4.73M)
1.03% less ownership
Funds ownership: 7.38% → 6.35% (-1%)
7% less funds holding
Funds holding: 28 → 26 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.05M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$536K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$435K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$218K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2.58M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.03M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$760K |
| 4 |
Renaissance Technologies
New York
|
-$412K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$247K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
GPCM
27
Granite Point Capital Management
Boston,
Massachusetts
| – | -$2.58M | -250,000 | Closed |
|
|
28
Point72 Asset Management
Stamford,
Connecticut
| – | -$1.03M | -100,000 | Closed |
|
|
EI
29
EAM Investors
Solana Beach,
California
| – | -$760K | -73,734 | Closed |
|
|
30
Renaissance Technologies
New York
| – | -$412K | -40,000 | Closed |
|
|
31
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$247K | -23,981 | Closed |
|
|
ASN
32
Advisory Services Network
Atlanta,
Georgia
| – | -$14K | -1,363 | Closed |
|
|
CSS
33
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$10K | -1,000 | Closed |
|
|
TPWA
34
TRUE Private Wealth Advisors
Salem,
Oregon
| – | -$10K | -1,000 | Closed |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| – | -$6K | -600 | Closed |
|
|
PFS
36
Prospera Financial Services
Dallas,
Texas
| – | -$2K | -175 | Closed |
|
INMB Hedge Fund Activity: Q4 2020 in Review
26 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2020, worth a combined $15M — up 46% from $10.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of INMB and 9 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.05M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $2.58M sold.
- 26 institutional investors held INmune Bio (INMB) as of Q4 2020, down from 28 in Q3 2020.
- Funds reported $15M of INmune Bio stock for Q4 2020, up 46% quarter-over-quarter.
- 9 funds opened new INmune Bio positions in Q4 2020 and 10 closed out, a net change of -1 holder.
- The largest INmune Bio buyer in Q4 2020 was Ikarian Capital, an estimated $2.05M added.
- The largest INmune Bio seller in Q4 2020 was Granite Point Capital Management, an estimated $2.58M sold.
Based on aggregated 13F filings for Q4 2020.